CL2018002577A1 - Forma física de un modulador sgr - Google Patents

Forma física de un modulador sgr

Info

Publication number
CL2018002577A1
CL2018002577A1 CL2018002577A CL2018002577A CL2018002577A1 CL 2018002577 A1 CL2018002577 A1 CL 2018002577A1 CL 2018002577 A CL2018002577 A CL 2018002577A CL 2018002577 A CL2018002577 A CL 2018002577A CL 2018002577 A1 CL2018002577 A1 CL 2018002577A1
Authority
CL
Chile
Prior art keywords
sgr
modulator
physical form
methyl
fenilbutan
Prior art date
Application number
CL2018002577A
Other languages
English (en)
Inventor
Deng Chaoyi
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2018002577A1 publication Critical patent/CL2018002577A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Amplifiers (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

UNA FORMA CRISTALINA DE 2,2-DIFLUORO-N-[(1R,2S)-3-METIL-1-{[1-(1-METIL-6-OXO-1,6-DIHIDROPIRIDIN-3-IL)-1H-INDAZOL-5-IL]OXI}-1- FENILBUTAN-2-IL]PROPANAMIDA (FORMA C), COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN Y SU USO EN TERAPIA.
CL2018002577A 2016-03-23 2018-09-10 Forma física de un modulador sgr CL2018002577A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2016/077095 WO2017161518A1 (en) 2016-03-23 2016-03-23 New physical form

Publications (1)

Publication Number Publication Date
CL2018002577A1 true CL2018002577A1 (es) 2018-12-21

Family

ID=58398193

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002577A CL2018002577A1 (es) 2016-03-23 2018-09-10 Forma física de un modulador sgr

Country Status (13)

Country Link
US (1) US10407404B2 (es)
EP (1) EP3433248B1 (es)
JP (1) JP6651648B2 (es)
KR (1) KR102168931B1 (es)
CN (1) CN109415348B (es)
AU (1) AU2017238341A1 (es)
CA (1) CA3016507C (es)
CL (1) CL2018002577A1 (es)
ES (1) ES2926059T3 (es)
IL (1) IL261367A (es)
MX (1) MX387467B (es)
SG (1) SG11201807228QA (es)
WO (2) WO2017161518A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12545648B2 (en) 2019-12-31 2026-02-10 Medshine Discovery Inc. Benzopyrazole compound
WO2023274040A1 (zh) * 2021-06-28 2023-01-05 南京明德新药研发有限公司 一种三唑并吡啶取代的吲唑类化合物的晶型及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1893588A1 (en) * 2005-06-10 2008-03-05 Boehringer Ingelheim International GmbH Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
TW200815361A (en) 2005-10-20 2008-04-01 Astrazeneca Ab Chemical compounds
WO2007114763A1 (en) 2006-03-31 2007-10-11 Astrazeneca Ab Sulphonamide derivates as modulators of the glucocorticoid receptor
EP1878717A1 (en) 2006-07-14 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Benzyl amines, a process for their production and their use as anti-inflammatory agents
EP1917963A1 (en) 2006-10-31 2008-05-07 Bayer Schering Pharma Aktiengesellschaft Cyclic phenyl-substituted indazols, a process for their production and their use as anti-inflammatory agents
WO2008055709A1 (en) 2006-11-08 2008-05-15 Bayer Schering Pharma Aktiengesellschaft Indazole and indole derivatives as anti -inflammatory agents
EP1921067A1 (en) 2006-11-08 2008-05-14 Bayer Schering Pharma Aktiengesellschaft Indole and indazole derivatives as anti-inflammatory agents
TW200829578A (en) * 2006-11-23 2008-07-16 Astrazeneca Ab Chemical compounds 537
JO2754B1 (en) * 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
WO2008079073A1 (en) 2006-12-22 2008-07-03 Astrazeneca Ab Indazolyl sulphonamide derivatives for the treatment of glucocorticoid receptor mediated disorders
EP1958934A1 (en) 2007-02-16 2008-08-20 Bayer Schering Pharma Aktiengesellschaft Tetrahydronaphthalenylamides, a process for their production and their use as anti-inflammatory agents
EP2062880A1 (en) 2007-11-22 2009-05-27 Bayer Schering Pharma Aktiengesellschaft 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents
EP2072509A1 (en) 2007-12-18 2009-06-24 Bayer Schering Pharma Aktiengesellschaft 1-Aryl-1H-quinoline-2-ones: process for their production and their use as anti-inflammatory agents
UY31832A (es) 2008-05-20 2010-01-05 Astrazeneca Ab Derivados de indazol sustituidos con fenilo y benzodioxinilo
EP2149558A1 (en) 2008-07-21 2010-02-03 Bayer Schering Pharma Aktiengesellschaft 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino-1-arylquinolin-2-ones, a process for their production and their use as anti-inflammatory agents
US8268820B2 (en) * 2009-03-26 2012-09-18 Hoffmann-La Roche Inc. 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds
JP2014527955A (ja) 2011-06-29 2014-10-23 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 糖質コルチコイド介在性障害の処置のための、インダゾリルアミド誘導体の結晶形
ES2751640T3 (es) * 2014-09-26 2020-04-01 Astrazeneca Ab Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y uso como moduladores de SGRM

Also Published As

Publication number Publication date
CN109415348A (zh) 2019-03-01
SG11201807228QA (en) 2018-10-30
WO2017161518A1 (en) 2017-09-28
JP6651648B2 (ja) 2020-02-19
KR20180117178A (ko) 2018-10-26
US20190106402A1 (en) 2019-04-11
CA3016507C (en) 2020-10-13
WO2017162747A1 (en) 2017-09-28
IL261367A (en) 2018-10-31
ES2926059T3 (es) 2022-10-21
CN109415348B (zh) 2021-09-03
AU2017238341A1 (en) 2018-09-13
MX2018011288A (es) 2019-06-13
US10407404B2 (en) 2019-09-10
CA3016507A1 (en) 2017-09-28
MX387467B (es) 2025-03-18
KR102168931B1 (ko) 2020-10-23
EP3433248B1 (en) 2022-06-22
EP3433248A1 (en) 2019-01-30
JP2019508474A (ja) 2019-03-28

Similar Documents

Publication Publication Date Title
CO2020000145A2 (es) Carboxamidas como moduladores de los canales de sodio
CL2020000122A1 (es) Métodos de tratamiento para la fibrosis quística.
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
ECSP19029982A (es) Moduladores de calpaínas y usos terapeuticos de los mismos
CL2013003313A1 (es) Compuestos derivados de 2,4-diaminoquinazolinas, sales o solvatos farmacéuticamente aceptables; composición farmacéutica que los comprende; y uso en el tratamiento de un trastorno en el que interviene la modulación de tlr7 y/o tlr8.
CL2018000897A1 (es) Composicion de fortalecimiento del cabello y metodo para fortalecer el cabello.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
GT201700063A (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos
CO2019008103A2 (es) Composiciones farmacéuticas para terapia de combinación
MX390126B (es) Nuevas isoformas de tripsina y su uso.
MX2017000676A (es) Oritavancina de alta pureza y metodo para producir la misma.
CL2020000056A1 (es) Nuevos derivados de xantina sustituidos.
DOP2018000034A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
CL2018002577A1 (es) Forma física de un modulador sgr
SV2019005811A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
MX2016014701A (es) (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.
DK3867244T3 (da) 4-pyrazin-2-ylmethylmorfolinderivater og anvendelse deraf som lægemiddel
CR20140526A (es) Dronedarona para uso en la leishmaniosis, formulaciones y asociaciones para uso en la leishmaniosis
MX2015012542A (es) Partículas de resinato de fenilefrina y su uso en formulaciones para productos farmacéuticos.
CL2019000997A1 (es) Forma cristalina de (1r,2r)-2-[4-(3-metil-1h-pirazol-5-il)benzoil-n-(4-oxo-4,5,6,7-tetrahidropirazolo[1,5-a]pirazin-3-il)ciclohexanocarboxamida.
MX388684B (es) Metodo de administracion de compuestos donadores de nitroxilo.
ECSP17025904A (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos
EA201991733A1 (ru) Фармацевтические композиции для комбинированной терапии
EA201992151A1 (ru) Фармацевтические композиции для комбинированной терапии